Cytokine polymorphism in noninfectious Uveitis

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 8, 2010, Pages 4133-4142

  Atan, Denize ^a   Fraser Bell, Samantha ^b   Plskova, Jarka ^c   Kuffova, Lucia ^c   Hogan, Aideen ^d   Tufail, Adnan ^e   Kilmartin, Dara J ^d   Forrester, John V ^c   Bidwell, Jeff ^f   Dick, Andrew D ^a   Churchill, Amanda J ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 10; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HEREDITY; HLA TYPING; HUMAN; IL10 GENE; IMMUNE DEFICIENCY; IRELAND; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TNFA GENE; UNITED KINGDOM; UVEITIS; ADOLESCENT; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HISTOCOMPATIBILITY TEST; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 77955900392     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4583     Document Type: Article

References (75)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491-500; discussion 500.
2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297.
3. Heinzlef O, Alamowitch S, Sazdovitch V, et al. Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand. 2000;101(1):36-40.
4. Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46(7):1851-1856.
5. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29(1):19-20.
6. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12): 3340-3348.
7. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603.
8. Schurmann M, Reichel P, Muller-Myhsok B, et al. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med. 2001;164(5):840-846.
9. Caspi RR. Animal models of autoimmune and immune-mediated uveitis. Drug Discovery Today: Disease Models. 2006;3(1):3-9.
10. Mattapallil MJ, Sahin A, Silver PB, et al. Common genetic determinants of uveitis shared with other autoimmune disorders. J Immunol. 2008;180(10):6751-6759.
11. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205(4):799-810.
12. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008;205(7):1535-1541.
13. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7(1):29-37.
14. Caspi RR. Ocular autoimmunity: the price of privilege? Immunol Rev. 2006;213:23-35.
15. Caspi RR, Sun B, Agarwal RK, et al. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye. 1997;11:209-212.
16. de Kozak Y, Naud MC, Bellot J, Faure JP, Hicks D. Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant rat strains. J Neuroimmunol. 1994;55(1):1-9.
17. Sun B, Sun SH, Chan CC, Caspi RR. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res. 2000;70(4):493-502.
18. Broderick C, Duncan L, Taylor N, Dick AD. IFN-gamma and LPSmediated IL-10-dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci. 2000;41(9):2613-2622.
19. Grajewski RS, Silver PB, Agarwal RK, et al. Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med. 2006;203(4):851-856.
20. Chen L, Yang P, Zhou H, et al. Diminished frequency and function of CD4_CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2008;49(8):3475-3482.
21. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4_CD25_ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(7):971-979.
22. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004;200(3):277-285.
23. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(_)CD25(_) T-cells from patients with type 1 diabetes. Diabetes. 2005;54(1):92-99.
24. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 1998; 11(3):255-264.
25. Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol. 2004;122(6):845-851.
26. Rizzo LV, Xu H, Chan CC, Wiggert B, Caspi RR. IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol. 1998;10(6):807-814.
27. Broderick CA, Smith AJ, Balaggan KS, et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol Ther. 2005;12(2):369-373.
28. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol. 2000;84(3):259-263.
29. Kilmartin DJ, Wilson D, Liversidge J, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. Br J Ophthalmol. 2001;85(3):281-286.
30. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335(8697):1078-1080.
31. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data; results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516.
32. BenEzra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis Scoring System. Springer Verlag; 1991.
33. Mensah FK, Gilthorpe MS, Davies CF, et al. Haplotype uncertainty in association studies. Genet Epidemiol. 2007;31(4):348-357.
34. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978-989.
35. Ke X, Cardon LR. Efficient selective screening of haplotype tag SNPs. Bioinformatics. 2003;19(2):287-288.
36. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24(1):1-8.
37. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993;23(1):224-231.
38. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation. 1995;60(10):1113-1117.
39. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
40. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39(5): 225-235.
41. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2(1):25-31.
42. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMSPCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol. 1999;7(2): 127-128.
43. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993;16(1):180-186.
44. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995;46(5):355-367.
45. Dudbridge F. UNPHASED user guide. Cambridge, UK: MRC Biostatistics Unit; 2006.
46. Seattle SNPs Variation Discovery Resource. Program for Genomic Applications. Seattle, WA: Fred Hutchinson Cancer Research Center, University of Washington.
47. A haplotype map of the human genome. Nature 2005;437(7063): 1299-1320.
48. Spink CF, Keen LJ, Middleton PG, Bidwell JL. Discrimination of suballeles present at the TNFd microsatellite locus using induced heteroduplex analysis. Genes Immun. 2004;5(1):76-79.
49. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2): 263-265.
50. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54(3):213-220.
51. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 2006;5(11):924-931.
52. Cope AP. Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology. 2003;42(6):716-731.
53. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol. 2001;166(6):3915-3922.
54. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349(9046):170-173.
55. Haukim N, Bidwell JL, Smith AJ, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun. 2002;3(6):313-330.
56. Warle MC, Farhan A, Metselaar HJ, et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl. 2003;9(2):170-181.
57. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5 flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42(6):1101-1108.
58. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A. 1998;95(16):9465-9470.
59. de Jong BA, Westendorp RG, Eskdale J, Uitdehaag BM, Huizinga TW. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol. 2002;63(4):281-285.
60. Im SH, Hueber A, Monticelli S, Kang KH, Rao A. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem. 2004;279(45): 46818-46825.
61. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol. 2006;133(3):293-300.
62. Posch PE, Cruz I, Bradshaw D, Medhekar BA. Novel polymorphisms and the definition of promoter 'alleles' of the tumor necrosis factor and lymphotoxin alpha loci: inclusion in HLA haplotypes. Genes Immun. 2003;4(8):547-558.
63. Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999;167:257-274.
64. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol. 1993;92(1):14-18.
65. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993;177(2):557-560.
66. Espel E, Garcia-Sanz JA, Aubert V, et al. Transcriptional and translational control of TNF-alpha gene expression in human monocytes by major histocompatibility complex class II ligands. Eur J Immunol. 1996;26(10):2417-2424.
67. Skoog T, Hamsten A, Eriksson P. Allele-specific chromatin remodeling of the tumor necrosis factor-alpha promoter. Biochem Biophys Res Commun. 2006;351(3):777-783.
68. Taylor JM, Wicks K, Vandiedonck C, Knight JC. Chromatin profiling across the human tumour necrosis factor gene locus reveals a complex, cell type-specific landscape with novel regulatory elements. Nucleic Acids Res. 2008.
69. Tsytsykova AV, Rajsbaum R, Falvo JV, Ligeiro F, Neely SR, Goldfeld AE. Activation-dependent intrachromosomal interactions formed by the TNF gene promoter and two distal enhancers. Proc Natl Acad Sci U S A. 2007;104(43):16850-16855.
70. Tsai EY, Falvo JV, Tsytsykova AV, et al. A lipopolysaccharidespecific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol Cell Biol. 2000;20(16):6084-6094.
71. Kuhnert P, Peterhans E, Pauli U. Chromatin structure and DNase I hypersensitivity in the transcriptionally active and inactive porcine tumor necrosis factor gene locus. Nucleic Acids Res. 1992;20(8): 1943-1948.
72. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem. 1998; 273(33):21178-21186.
73. Barthel R, Goldfeld AE. T cell-specific expression of the human TNF-alpha gene involves a functional and highly conserved chromatin signature in intron 3. J Immunol. 2003;171(7):3612-3619.
74. Seiler-Tuyns A, Dufour N, Spertini F. Human tumor necrosis factoralpha gene 3_ untranslated region confers inducible toxin responsiveness to homologous promoter in monocytic THP-1 cells. J Biol Chem. 1999;274(31):21714-21718.
75. Koch CM, Andrews RM, Flicek P, et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res. 2007;17(6):691-707.